Expanded Phase I Pazopanib and Everolimus in Advanced Solid Tumors and Previously Treated Advanced Urothelial Cancer

NCT ID: NCT01184326

Last Updated: 2019-10-02

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 23 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2011-01-31
• Study Completion Date: 2017-03-31

Brief Summary

This research study is evaluating the combination of pazopanib and everolimus in patients that have a malignancy that is metastatic or unresectable and for which standard curative or palliative measures do not exist or are no longer effective, or metastatic or locally advanced unresectable kidney cancer. In this research study the investigators are testing the safety of the combination of pazopanib and everolimus and finding the appropriate doses to use for further studies.

Detailed Description

This protocol has two parts, Phase I Dose Finding and Phase 1 Expansion. Once the maximum tolerated dose has been identified in the Phase I Dose Finding portion, a Phase I expansion cohort of patients with metastatic or locally advanced unresectable kidney cancer will be enrolled.

Conditions

Solid Tumor; Kidney Cancer

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Dose Level 0: Everolimus 5mg + Pazopanib 600 mg

Everolimus 5mg + Pazopanib 600 mg once daily for 28 days each cycle Participants were treated until disease progression, unacceptable toxicity or patient withdrawal.

Group Type: EXPERIMENTAL

pazopanib

Intervention Type: DRUG

everolimus

Intervention Type: DRUG

Dose Level -1: Everolimus 5mg + Pazopanib 400 mg

Everolimus 5mg + Pazopanib 400 mg once daily for 28 days each cycle Participants were treated until disease progression, unacceptable toxicity or patient withdrawal.

Group Type: EXPERIMENTAL

pazopanib

Intervention Type: DRUG

everolimus

Intervention Type: DRUG

All Phase I Dose Expansion Participants

All phase I dose expansion participants received Everolimus 5mg and Pazopanib at the maximum tolerated dose established in the dose finding part of the study.

Group Type: EXPERIMENTAL

pazopanib

Intervention Type: DRUG

everolimus

Intervention Type: DRUG

All Phase I Participants

All phase I participants received Everolimus 5mg and Pazopanib according to the established dose escalation schedule or the maximum tolerated dose established in the dose finding part of the study.

Group Type: EXPERIMENTAL

pazopanib

Intervention Type: DRUG

everolimus

Intervention Type: DRUG

Interventions

pazopanib

Intervention Type: DRUG

everolimus

Intervention Type: DRUG

Other Intervention Names

Votrient; RAD001

Eligibility Criteria

Inclusion Criteria

• Phase I: Participants must have histologically confirmed malignancy that is metastatic or unresectable and for which standard curative or palliative measures do not exist or are no longer effected.
• Expansion Cohort Only: Participants must have histologically or cytologically confirmed metastatic or locally advanced unresectable kidney cancer.
• Expansion Cohort Only: Participants must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension at 20mm or greater with conventional techniques or as 10mm or greater with spiral CT.
• Expansion Cohort Only: Previously treated with at least one anti-angiogenic agent, including but not limited to bevacizumab, sunitinib, or sorafenib. No more than 4 lines of prior systemic therapy for kidney cancer, mTOR pathway inhibitors other than RAD001 are allowed.
• 18 years of age or older
• Life expectancy of greater than 3 months
• ECOG performance status of 0 or 1
• Normal organ and marrow function as outlined in the protocol
• Able to swallow oral medications
• Resolution of any pre-existing toxicity from prior therapy to NCI CTCAE v4.0 grade 1 or less
• Women are eligible to participate if she is of non-child bearing potential or agrees to use adequate contraception
• Female subjects who are lactating should discontinue nursing prior to the first dose of study drug and should refrain from nursing throughout the treatment period and for 14 days following the last dose of study drug
• A male with a female partner of childbearing potential must use a barrier method of contraception or abstinence during the study

Exclusion Criteria

• Participants who have had chemotherapy or radiotherapy within 4 weeks prior to entering the study or thos who have not recovered from adverse events due to agents administered more than 4 weeks earlier. Current treatment with leuprolide or other GnRH agonists is permitted on the Phase 1 portion of the study.
• Participants may not be receiving any other study agents.
• Prior RAD001 or pazopanib therapy
• History of clinical evidence of central nervous system (CNS) metastases or leptomeningeal carcinomatosis, except for individuals who have previously treated CNS metastases, are asymptomatic, and have had no requirement for steroids or anti-seizure medication for 6 weeks prior to the first dose of study drug.
• Known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to pazopanib or everolimus
• History of any of the following cardiovascular conditions within the past 6 months: Cardiac angioplasty or stenting; myocardial infarction; unstable angina; coronary artery by-pass graft surgery; symptomatic peripheral vascular disease; Class III or IV congestive heart failure
• Poorly controlled hypertension
• History of cerebrovascular accident, pulmonary embolism, or untreated deep venous thrombosis within the past 6 months
• Prior major surgery or trauma within 28 days prior to first dose of study drug, and/or not recovered from effects of that surgery, and/or presences of an non-healing wound, fracture or ulcer, or patients that may require surgery during the course of treatment
• Evidence of active bleeding or bleeding diathesis
• Known endobronchial lesions or involvement of large pulmonary vessels by tumor
• Hemoptysis within 6 weeks of the first dose of study drug
• Clinically significant gastrointestinal abnormalities that may increase the risk of GI bleeding
• Expansion Cohort Only: Currently active second malignancy other than non-melanoma skin cancers
• Presence of uncontrolled infection
• Liver disease such as chronic cirrhosis, active hepatitis or chronic persistent hepatitis
• Uncontrolled diabetes
• Pregnant or breastfeeding
• Chronic treatment with systemic corticosteroids or other immunosuppressive agent
• Treatment with strong CYP3A4 inhibitors
• Treatment with strong CYP3A4 inducers
• Patients should not receive immunization with attenuated live vaccines within one week of study entry or during study period
• Prolongation of corrected QT interval > 480msecs
• History of malabsorption syndrome, disease significantly affecting gastrointestinal function or major resection of stomach or small bowel that could interfere with absorption, distribution, metabolism, or excretion of study drugs
• Any ongoing toxicity from prior anti-cancer therapy that is greater than grade 1 and/or that is progressing in severity.
• Any serious and/or pre-existing medical, psychiatric, or other condition that could interfere with subject safety, obtaining informed consent or compliance with study procedures
• HIV-positive individuals on combination antiretroviral therapy

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Beth Israel Deaconess Medical Center

OTHER

Sponsor Role: collaborator

Brigham and Women's Hospital

OTHER

Sponsor Role: collaborator

GlaxoSmithKline

INDUSTRY

Sponsor Role: collaborator

Novartis

INDUSTRY

Sponsor Role: collaborator

Dana-Farber Cancer Institute

OTHER

Sponsor Role: lead

Responsible Party

Mark Pomerantz, MD

Assistant Professor of Medicine, Harvard Medical School

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Mark Pomerantz, MD

Role: PRINCIPAL_INVESTIGATOR

Dana-Farber Cancer Institute

Locations

Beth Israel Deaconess Medical Center

Boston, Massachusetts, United States

Dana-Farber Cancer Institute

Boston, Massachusetts, United States

Countries

United States

References

Bellmunt J, Lalani AA, Jacobus S, Wankowicz SA, Polacek L, Takeda DY, Harshman LC, Wagle N, Moreno I, Lundgren K, Bosse D, Van Allen EM, Choueiri TK, Rosenberg JE. Everolimus and pazopanib (E/P) benefit genomically selected patients with metastatic urothelial carcinoma. Br J Cancer. 2018 Sep;119(6):707-712. doi: 10.1038/s41416-018-0261-0. Epub 2018 Sep 17.

Reference Type: RESULT

PMID: 30220708 (View on PubMed)

Provided Documents

Document Type: Study Protocol and Statistical Analysis Plan

View Document

Other Identifiers

10-166

Identifier Type: -

Identifier Source: org_study_id